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ABSTRACT 
 
In silico models are essential for the development of integrated alternative methods to 
identify organ level toxicity and lead towards the replacement of animal testing. These 
models include (quantitative) structure-activity relationships ((Q)SARs) and, importantly, the 
identification of structural alerts associated with defined toxicological endpoints. Structural 
alerts are able both to predict toxicity directly and assist in the formation of categories to 
facilitate read-across. They are particularly important to decipher the myriad mechanisms of 
action that result in organ level toxicity. The aim of this study was to develop novel structural 
alerts for nuclear receptor (NR) ligands that are associated with inducing hepatic steatosis. 
Current knowledge on NR agonists was extended with data from the ChEMBL database of 
bioactive molecules and from studying NR ligand-binding interactions within the protein data 
base (PBD). A computational structural alerts based workflow was developed using KNIME 
from these data using molecular fragments and other relevant chemical features. In total 214 
structural features were recorded computationally as SMARTS strings and, therefore, they 
can be used for grouping and screening during drug development and risk assessment and 
provide knowledge to anchor adverse outcome pathways (AOPs). 
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INTRODUCTION 
Nuclear receptors (NR) belong to a large superfamily of ligand-inducible transcription factors 
that, upon activation, mediate the expression of their target genes.1 The ligands associated 
with NR activation are usually lipophilic, small in size and include the following chemical 
classes: endogenous steroids, oxysterols, thyroid hormones as well as various lipids and 
retinoids.2,3 NRs are essential for the regulation of specific target genes that are involved in 
development, metabolism, reproduction and other vital physiological processes. Upon ligand-
induced activation, NRs elicit a rapid cellular adaptation to environmental changes via the 
induction of the required genes and pathways.4  
Due to their involvement in many essential processes within the body, the search for novel 
ligands for nuclear receptors (NRs) has intensified in order to identify possible preventative / 
therapeutic treatments for a wide range of diseases including diabetes, cancer, cardiovascular 
diseases, atherosclerosis, neurodegenerative diseases and obesity.3,4 For example, the 
oestrogen receptor (ER) antagonist tamoxifen is used for the treatment of ER positive breast 
cancer.5-7 As NR ligands are widely used it is imperative their safety is considered, as there 
are reports of NR ligands leading to drug induced liver injury (DILI), such as liver steatosis, 
due to the bio-activation of drugs (or metabolites) and / or the induction of hepatotoxic 
pathways. 8-11  
Traditional approaches to determine safety have required the use of animal tests. However, 
the promotion of what is termed “21st Century Toxicology” has led to the move from 
traditional animal testing safety assessment methods to the use of integrated alternative 
strategies which utilise toxicokinetics, computational models and in vitro testing.12-14 The 
shift in the mind set occurring within toxicology has given rise to the concept of the Adverse 
Outcome Pathway (AOP) framework.13-17 An AOP describes the causal linkage between a 
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molecular initiating event (MIE) and an adverse outcome at individual or population 
levels.12,17 The AOP developed within the current AOP Wiki knowledge base (AOP-KB) for 
hepatic steatosis defines liver toxicity as the adverse effect and nuclear receptor binding 
being the MIE, thus this knowledge provides the starting point for computational 
methods.14,17,18  
Computational methods include the use of (quantitative) structure-activity relationships 
((Q)SARs) as well as other approaches including biokinetic models. QSARs require the use 
of mathematical models in order to predict biological activity of chemicals from their 
structure or physico-chemical properties. An SAR is a qualitative link between a certain 
molecular substructure to a specific biological activity.19 Structural alerts (SA) derived from 
SARs can aid in the formation of categories with similar chemicals that are associated to 
share the same SAR. The assessment of these category members can, in turn, allow for the 
better definition of the domain of the SA.19,20 SA are common structural fragments that are 
associated with a specific toxicity which very often have mechanistic rational to support these 
links – with reference to an AOP this is in terms of the MIE. 19-21 SAs are already used to 
screen potential lead chemicals for idiosyncratic toxicity within industry settings.23 Thus, 
through knowledge of the AOP, they can form the first step in understanding the links from a 
specific chemical to its possible mechanistic pathways and those organs that may be 
affected.19 For the AOP concept to be applied, particularly to support category formation and 
read-across, SA associated with a MIE for a particular adverse pathway must be elucidated 
and described. 
The use of new (toxicological and informatics) approaches can help to aide in the formation 
of SAs; for instance, applying freely available software and utilising the growing number of 
open access databases of toxicological information.24 For this study, the new methods 
approaches used included the ChEMBL database of bioactive molecules (with >1.5 million 
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compounds and 9,000 biological targets), KoNstanz Inforamtion MinEr (KNIME) software 
that allows the analysis/ mining of data and can be used to build predictive models and the 
protein data bank (PBD), a database of > 100,000 crystallographic structures of proteins e.g. 
receptors which can be analysed alongside software such as PyMOL and Marvin Beans, a 
ChemAxon suite of programmes that allow the visualisation and drawing of chemicals, all of 
which are freely available.25-29 
Mellor et al. (2015) reviewed the NRs linked to liver injury, identifying ten NRs that can 
cause the onset of hepatic steatosis, these are summarised in Table 1.17 Each of these NRs is 
associated with a definable mechanism of action and / or toxicity pathway that could form the 
basis of an AOP. A MIE is definable for each NR, therefore with analysis of suitable data for 
NR binding, this raises the possibility of defining a suite of SA which could form the basis of 
toxicity prediction or grouping. Thus, the aim of this study was to develop a set of SAs for 
the NRs associated with hepatic steatosis listed in Table 1. This was achieved with reference 
to the MIEs for the mechanisms of action and utilised the ChEMBL database as a source of 
information. A workflow was created to collate knowledge that can predict binding to the NR 
listed in Table 1.25 The workflow was developed in a two-step process. The first step involved 
identifying the physico-chemical properties that define the chemical space/ domain of 
agonists of the NR through the calculation of descriptors from the chemical structure. The 
second step involved the identification of structural features associated with NR binding 
which were then coded into SMARTS strings so they could be implemented in the workflow. 
The identification of structural features was performed by studying the ligand-binding 
interactions of the agonists to their respective NR using the PDB files viewed in PyMol and 
by studying the literature associated with these files (referenced within PDB).27,28,30 The 
workflow can be used for hazard assessment, screening of potential ligands for chemical 
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leads or grouping. The workflow is freely available to use and download from COSMOS 
Space (http://cosmosspace.cosmostox.eu/app/login). 
 
TABLE 1 HERE 
 
METHODS 
Identifying chemical structures with relevant NR binding data from ChEMBL  
The 10 NR listed in Table 1 were searched for within the online ChEMBL database (Version 
3.9) using their names and standard nomenclature identifiers in order to find agonists.25 To 
identify agonists, the names and / or nomenclature of the NRs, as reported in Table 1, were 
entered into the search bar within the online ChEMBL website with Homo sapiens selected as 
the species of interest. Data retrieved were downloaded to comma-separated values (.csv) 
files and later saved in an Excel spreadsheet. Those data with pChEMBL values were selected 
and all other chemicals without these values were removed. The pChEMBL value is an 
approach to standardise different types of activity values.31 In addition, the following 
information was obtained from ChEMBL: the chemical name, molecular formula, SMILES 
string of each agonist, the assay type (e.g. receptor activation), activity value (reported as Ki, 
Kd, AC50, IC50, and EC50) and other relevant information regarding the assay. Only 
agonistic Ki, Kd, AC50 or EC50 values were utilised to remove data relating to inhibition of 
receptors (e.g. those with IC50 values / Ki values) and to ensure receptor activation data were 
considered. Chemicals were then ordered by pChEMBL value (highest to lowest) and those 
with a pChEMBL of <5 removed. The pChEMBL of > 5 was used as the threshold for 
activity as when studying the ChEMBL data this was the point at which most of chemicals 
were considered active and has been utilised previously.34,31 Agonists with pChEMBL values 
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above the threshold value were studied using the Marvin Bean (version 1.6) chemical 
visualisation software in order to find common structural features associated with NR 
activation; these features were recorded as SMARTS strings.29,30  
Analysis of ligand-binding information from the Protein Data Bank (PDB) 
The PDB was investigated in conjunction with the list of agonists and associated data 
obtained from ChEMBL to further study the ligand-binding of agonists to their respective NR. 
The NR names /nomenclature (Table 1) were searched for on the PDB website and human 
NR files containing information about agonistic binding to human NR structures were 
selected. The selected files were viewed to study their ligand-protein interactions using 
PyMOL (version 1.3) and the linked publications provided within the PDB were read to find 
the key amino acid residues on the NR binding site that have been shown to interact with 
specific functional groups on the ligand. The functional groups on the agonists needed for 
these essential binding interactions with the NR binding site such as hydroxyl moiety group 
were then drawn as SMILES strings and added to form the rules of the workflow. 27, 28, 30  
 
Calculation of Molecular Descriptors 
Molecular properties and other descriptors for the agonists were calculated using the CDK 
node in KNIME (version 3.2).26 SMILES strings for the ligands were retrieved from 
ChEMBL and then cleaned (removal of salts, inorganics and mixtures). The SMILES were 
entered into the CDK node and all available descriptors (33 available within CDK node) were 
calculated. Descriptors were identified that described features relevant to ligand-protein 
interactions and gave a specific range of values for each NR. In total eight descriptors were 
used: molecular weight (MW, describing molecular size), the calculated logarithm of the 
octanol-water partition coefficient (xlogP, lipophilicity), vertex adjacency matrix (VAIM, 
molecular size and complexity), number of hydrogen bond acceptors / donors (HBA/ HBD, 
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binding interactions), eccentric connectivity index (ECI, structural complexity), topical polar 
surface area (TPSA, relative polarity) and the number of rotatable bonds (RB, molecular 
flexibility and entropy). 
Development of Workflows 
KNIME (version 3.2) was used to build a structural feature-based workflow to screen for 
ligands predicted to bind to NR that are associated with the onset of hepatic steatosis (Table 
1). The workflows executed rules based on physico-chemical properties and structural 
features established through studying relevant pChEMBL values and the structural 
information within PDB. The main KNIME workflow is an amalgamation of eight smaller 
workflows for each NR making screening chemicals fast and easy for users. Each of these 
individual workflows is made up of two steps. The first calculates physico-chemical 
properties of the chemicals being screened to identify if the chemicals are in the chemical 
space defined previously (descriptor ranges applied). The second step runs the chemicals 
being screened against the structural features found to be essential for receptor binding that 
have been developed for each NR. In summary the workflow firstly identifies if a compound 
is in the chemical space associated with being an agonistic binder, then whether it has the 
structural features required for binding, which is an informed method of grouping for receptor 
mediated effects. 
The workflow developed allows users to enter one chemical to be screened for NR binding 
(either via a .csv file containing the SMILES string for the chemical or by drawing the 
chemical structure using the drawing tool available) or via a batch  process (using a .csv file 
containing the SMILES for all the chemicals being screened). The output of the workflow is a 
table of all the chemicals that were identified as binders to one or more of the NR listed in 
Table 1 (note: RAR and RXR are combined and CAR is not present within the workflow, see 
the CAR section in the Results), the NR that they are predicted to bind to are listed. If a batch 
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is run and no chemicals are identified as possible binders, a message will appear to let the 
user know that their chemicals are deemed not to be a binder to the NRs listed. 
 
 
RESULTS 
Data and information obtained from ChEMBL and PDB 
Data and other information about ligand binding were extracted from ChEMBL and the PDB 
for the ten NR listed in Table 1. The number of agonists obtained from ChEMBL, those 
deemed to be active, the range of pChEMBL values found for each NR and the number of 
human PDB files (which contain crystallographic representations of the NRs binding with 
agonists) found associated with each NR is summarised in Table 2. 
 
TABLE 2 HERE 
 
Descriptor ranges applied 
Descriptors were calculated within KNIME using the CDK node. Descriptors were calculated 
for all agonists collected from ChEMBL that were identified as active (pChEMBL > 5). Eight 
descriptors were chosen in total and these were selected as they gave information relevant for 
ligand binding/ ligand shape and so define the chemical space for the properties needed to 
bind to the NR of interest. A summary of the ranges used for the molecular descriptors and 
applied for each NR within the workflow is presented Table 3 below. 
 
TABLE 3 HERE 
 
Ligand-protein binding information and building of SA 
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From studying the ligand binding interactions found within the crystallographic PDB files of 
human NR to known agonists, key structural features that were shown to be essential were 
identified. These structural features were classed as essential as they occurred in many of the 
PDB files showing agonistic binding for the NR, also the papers associated with each PDB 
file made reference to these important structural features, therefore this knowledge was built 
upon and added to using knowledge obtained from ChEMBL (chemical structure obtained 
and activity values for known agonists of each NR). The structural features that were 
developed for the workflow are summarised below for each NR studied. N.B the tables 
showing structural features found for each NR are only shown for the AHR receptor – all 
others are found within the supporting information. 
AHR 
The PDB files associated with agonistic binding to the human AHR receptor were studied 
along with the shape of the agonists obtained from ChEMBL. From these the ligand-binding 
patterns and those chemical features present in all known AHR agonists were identified. It 
was found that ligands must form interactions (usually via hydrogen bonds) with the key 
residues Met328, Tyr353 and Phe367 found within the AHR binding pocket in order to 
activate the AHR NR.33 These structural features were then coded into SMARTS strings.30 
The AHR workflow was split into two parts, firstly the chemical must contain at least one of 
the backbone ring structures as reported in Table 4 (showing the SMARTS strings and visual 
representations) as these were observed as being essential to fitting into the binding pocket. 
Secondly the chemical must contain either one of the oxygen functional groups seen in Table 
5 or substitutes for oxygen (nitrogen/chlorine groups) reported in Table 6. The 
oxygen/nitrogen functional groups were observed to be essential to form hydrogen bonds 
between the ligand and the ligand binding pocket of the AHR. 
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TABLE 4 HERE 
TABLE 5 HERE  
TABLE 6 HERE  
 
CAR 
When searching for data associated with the CAR NR within the ChEMBL database, only 40 
chemical structures could be found. Furthermore, no pChEBML values were assigned to 
these chemicals. As the quantity and quality of the data available for CAR were limited, this 
NR was excluded from model development. This should be noted as a subject for further 
investigation in future to develop structural alerts for this NR and also for the development of 
AOPs.  
ER 
The binding of ER agonists was observed (within the PDB files containing crystallographic 
representation of agonists binding to the human ER). It was found that a ligand must interact 
with the key residues Arg346, Glu 305 and H13475 within the ER binding domain in order 
for ER activation.34 The bonds formed in order for this interaction to occur involved 
hydrophobic van der Waals interactions within the lipophilic pocket. The structural features 
of ligands that occurred in the PDB files were coded into SMARTS patterns. The binding of 
ER agonists was shown to be similar to other steroid hormone NRs with the exception that 
binding was found to be different for ER agonists with a higher molecular weight. Therefore 
the ER workflow first splits the chemicals being screened based on MW within the range 
(700< MW < 2250), the MW range was selected based on the MW of the known binders 
within ChEMBL. Those chemicals with a MW within this range were checked against the 
steroid structure check (Supplementary data - Table S1). Those chemicals with a MW less 
than 700 pass through the usual descriptor checks and then proceed to the structural feature 
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screening. Similar to the AHR rules, the chemical must contain at least one of the essential 
scaffold ring SA (Supplementary data - Table S2) and one of the oxygen functional groups 
(Supplementary data - Table S3) or nitrogen functional group (Supplementary data - Table 
S4). The oxygen and nitrogen functional groups were found to form essential hydrogen bonds 
between the ligands and the ligand binding pocket. 
FXR 
Structural features implemented for FXR screening are expressed in Supplementary data 
Table S5 and S6. The residuals of arginine and histidine, sometimes incorporating water 
molecules, form hydrogen bonds with carboxylic groups (3BEJ). The threonine, asparagine 
and glutamic acid residues may form further hydrogen bonds, in particular to oxygens (4II6, 
3BEJ). Sub-structural patterns in FXR ligand are mainly defined by oxygens, and to a lesser 
extent, nitrogens, sulphurs and halogens, and the manner in which they are attached to 
aromatic and aliphatic ring structures. Many ligands do not have significant structural 
resemblance to the endogenous ligands, such as chenodeoxycholic acid.35 
GR 
The conclusions from the PDB files and literature searches revealed that ligands that bind 
with high affinity to GR contain a ketone group (or other similar substitute group) which 
forms hydrogen bonds between the ARG-611 and Gln-570 amino acid residues on the ligand 
binding pocket of the GR.32 The hydrogen atom from the 17b-hydroxyl group has a partial 
positive charge which allows it to interact and form bonds with highly electronegative atoms 
that are bound to an amino acid residue.  These essential features were coded into SMARTS 
strings. The first step within the GR workflow splits the chemicals depending on MW. 
Chemicals that had MW within this range (610 < MW < 1200) went through one check to 
look for the ring structure as described in supplementary data, Table S7. Those chemicals 
with a MW less than 610 are screened against the descriptor ranges (Table 3) and to identify 
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essential structural features. The chemical must contain a backbone ring structure 
(Supplementary data - Table S8) and must also contain either an oxygen group 
(Supplementary data - Table S9) or a nitrogen group (Supplementary data – Table S10). The 
binding observed for GR actives was similar to that observed for other steroid based NR. 
They have specific ring structures with many oxygen / nitrogen functional groups that help to 
form strong hydrogen bonds between the ligand and ligand binding pocket.  
LXR 
LXR actives were studied and the sub-structural features were coded into SMARTS strings 
(Supplementary data - Tables S11 and S12). A potential ligand contains a ring backbone, 
which may have interactions with phenylalanine, tryptophan and histidine residues, in 
particular π-π stacking. Furthermore, the compound must also contain functional groups, in 
particular terminal oxygens, interacting with arginine or threonine residues and the secondary 
amine of a leucine (PDB: 3LOE, 4NQA, 4DK7), as can be seen in Figure 1 showing 
hydrogen bonding between the ARG319 and LEU330 residues of the LXR binding pocket to 
the oxygen groups of the ligand. 
 
FIGURE 1 HERE 
 
PPAR 
PPAR actives were studied and the sub-structural features were coded into SMARTS strings. 
The chemical must not contain a steroid backbone (Supplementary data - Table S13) but must 
contain one of the specific “diaromatic” scaffold and one of the specific functional groups in 
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order to be an active. Additional alerts describe fatty acid- and retinoid-like compounds, 
which may have moderate PPAR affinity (Supplementary data - Tables S14, S15 and S16).  
PXR 
It was found that ligands of the PXR must form interactions (usually hydrogen bonds) with 
the key residues Ser 208, Ser247, GLn285, His407 and Arg410 within the PXR binding 
pocket in order for PXR activation to occur.36 The sub-structural features of PXR actives 
studied were coded into SMARTS strings. Similar to the other steroidal NR, the chemical 
must contain at least one of the essential scaffold ring SA (Supplementary data - Table S17) 
and one of the oxygen functional groups (Supplementary data - Table S18) or nitrogen 
functional group (Supplementary data - Table S19). The oxygen and nitrogen functional 
groups were found to form hydrogen bonds between the ligands and the ligand binding 
pocket. 
RAR/RXR 
After observing the RAR and RXR receptors separately it was noted that their actives had 
very similar binding patterns and it was decided to combine them into one workflow. 
Generally RAR/RXR ligands are lipophilic, but there are a few compounds which are active 
without being lipophilic (XLogP < 2.2), e.g. n-phosphono-L-phenylalanyl-L 
alanylglycinamide with an XLogP of -2.4. As these compounds have peptide-like bonds, 
XLogP exception rules were created (Supplementary data - Table S21). To narrow down the 
compounds passing through this alert, such as inactive amino sugars, a further filter 
(Supplementary data - Table S22) was used. As shown in Figure 2, there are certain groups 
(in particular double bond oxygens), binding to arginine and serine residues, e.g. the 
hydrogen bond between ARG278 or SER289 and an oxygen of a ligand’s carboxylic group 
within the RAR domain. The responsible structural features are described in the alerts 
(Supplementary data - Table S23). Furthermore RAR/RXR ligands contain at least one ring 
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structure, which could be aromatic or aliphatic, e.g. cyclohexene of retinoic acid, as 
expressed in the SA (Supplementary data - Table S24). 24, 37 
FIGURE 2 HERE 
Testing the screening workflow 
The ChEMBL chemicals deemed to be active via their pChEMBL value were used to test if 
all of the chemicals that are known agonists for the NR of interest (Table 1) are identified by 
the screening workflow. The results demonstrated that 100% of the chemicals that are known 
binders were successfully predicted as binders to their associated NR showing that the 
workflow was accurate at identifying known binders. 
 
DISCUSSION 
21st Century Toxicology relies heavily on the development of alternative testing methods 
(computational, biokinetics, in vitro) as opposed to the traditional extensive animal methods 
used previously. Alternative approaches now favour the inclusion of computational models, 
however, traditional in silico models (QSARS/SARs) have struggled in the past to deal with 
organ level toxicity. Despite this, recently there has been some improvement through the use 
of SA, especially focussed on MIEs.20-22 In general, SA are well developed for MIEs 
involving a covalent event as demonstrated by the many profilers (e.g. for protein or DNA 
binding) implemented in the OECD QSAR Toolbox. It remains much more difficult to 
develop profilers for receptor mediated toxicity, with the current state of the art being MIE-
derived 2D descriptors.20-22,3839 Whilst these issues are recognised, encouraging recent studies 
have shown that it is possible that useful information and models, including profilers, can be 
developed for receptor mediated toxicity.40,41  
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Whilst it is becoming common place to code 2D interactions e.g. protein / DNA binding as 
molecular fragments, the next challenge lies with the grouping of receptor mediated effects. 
Ultimately the modelling of must receptor-ligand interactions must address the use of 
molecular modelling and other types of molecular design software, and a framework for 
undertaking this task has been presented recently.40 Despite the simplicity of a 2D approach, 
progress can be made rapidly,22 and such profilers are amenable to use in e.g. the OECD 
QSAR Toolbox.42 In this study the issue of the capture of information relating to MIE has 
been addressed, in part, by the use of structural alerts based workflows. SA can be used both 
as a direct predictor of toxicity and also for grouping chemicals for read across. Through the 
development of AOPs, SA can be used collectively if they have the same MIE, our 
understanding of this MIE can then provide a linkage to mechanistic pathways and the 
adverse effects induced via these pathways. AOPs are now integral to risk assessment, 
therefore, AOP development is important and the role SA play in their implementation is 
essential. 
There are many (Q)SAR models available for the prediction of NR mediated effects.43 
Therefore, the purpose of this study was not to repeat previously undertaken work but rather 
to build on existing knowledge to create a new set of SA/ structural features that can be 
implemented in an in silico workflow. This investigation has focused on NR previously 
linked to the onset of hepatic steatosis.17 Within this study the use of new generation 
resources (PBD, pChEMBL, KNIME, PyMOL, Marvin Beans) has been a key element. This 
demonstrated how existing data may be used in future studies to create knowledge regarding 
toxicological interactions. A total of 12,713 chemicals were identified in ChEMBL that were 
linked to NR and could be used in this study (with a pChEMBL >5). In addition 624 human 
PDB files showed binding information of ligands to the NR of interest for this study. These 
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figures show the vast amount of current data that are available and, when linked to AOPs, 
have the potential to provide a goldmine of information. 
Generally all workflows in this study can be divided into two essential steps. The first step 
involves the screening for ligand-specific physico-chemical descriptors and the second step 
involves the use of sub-structural features. The sub-structural features produced for most of 
the NR workflows follow a similar pattern of scrutinising for key scaffolding structures (e.g. 
ring structures) and then further screening for essential functional groups. However, there are 
a few exceptions such as for RXR and PPAR (which have some exclusion rules) and for GR, 
AR, ER and PXR (which have high MW filter to account for those ligands that were larger 
and had different receptor binding patterns compared the low MW ligands).  
Within the literature it remains unclear what role the different nuclear receptor subtypes play 
in terms of activation of the pathways associated with each NR.44 As the binding of ligands to 
the different receptor subtypes was observed to overlap, it was decided to combine the 
subtypes into one screening workflow. It would have been challenging to develop structural 
features for one specific receptor subtype as many ligands are able to bind to different 
subtypes albeit sometimes with different affinities. For example, the ER agonist raloxifene 
has PChEMBL value of 10.52 for the ERα and a PChEMBL value of 8.8 for the ERβ. Also it 
cannot be determined if one ligand only binds to one receptor subtype due to the constraints 
of the data available in the ChEMBL database. Therefore a NR workflow, such as for ER, is a 
combined workflow incorporating all receptor subtypes, such as ERα and ERβ. It was noted 
that the ligands of some of the NR were similar, particularly those that are specific for 
retinoids (e.g. RAR and RXR ligands) and steroids (e.g. AR, ER and GR ligands). This 
means that ligands may have the ability to activate many NRs (to a certain extent). As 
predictions for promiscuous receptors can be difficult, the full set of predictions is given 
within the output file of the screening workflow.  
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It should be noted that the workflow can be used for hazard identification to inform which 
chemicals require further testing rather than for risk assessment purposes. This is due to the 
buffers applied when applying the chemical descriptor ranges and when making the structural 
alerts. This generalistic approach has the advantage of capturing new chemicals that have a 
similar structure to previously known binders but with the addition/ removal of structural 
features e.g. a methyl group that may still have the potential of causing receptor activation. 
The disadvantage of this approach is that the model should not be used for risk assessment 
purposes alone; however, it can be used as an informed approach for hazard identification 
which with the combination of other testing approaches (in vitro testing) can act as risk 
assessment.  
 
CONCLUSIONS 
214 structural features were developed from MIEs associated with AOPs and combined with 
eight different descriptors to create a decision based workflows for each NR. The individual 
NR workflows have been amalgamated into one large screening workflow for all NRs 
investigated and with the focus being the NRs associated with the onset of hepatic steatosis. 
This study highlights that modern technologies (PDB, CheMBL, KNIME) provide new 
opportunities to build alerts and use the information potentially contained with AOPs. This 
study is the first to produce a SA based workflow of this size for a receptor mediated toxicity, 
in this case linked to hepatic steatosis as the target organ adverse effect through the AOP. The 
workflow produced has addressed the problem of grouping chemicals that have hepatic 
steatosis as their endpoint, a previously difficult task.  
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Table 1: Nuclear receptors associated with hepatic steatosis and abbreviations as defined by Mellor et 
al 2015.17 
Nuclear receptor name Abbreviation Nomenclature Identification 
Aryl Hydrocarbon Receptor  AHR bHLHe76 
Constitutive Androstane Receptor  CAR NR1I3 
oEstrogen Receptor  ER NR3A1/2 
Farnesoid X Receptor  FXR NR1H4/5 
Glucocorticoid Receptor  GR NR3C1 
Liver X Receptor  LXR NR1H2/3 
Peroxisome Proliferator-Activated Receptor  PPAR NR1C1-3 
Pregnane X Receptor  PXR NR1I2 
Retinoic Acid Receptor  RAR NR1B1-3 
Retinoid X receptor RXR - 
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Table 2: Summary of the data and information obtained from ChEMBL and the PDB for the different 
NR agonists 
 
Nuclear 
receptor 
Number of agonists obtained from 
ChEMBL 
Range of 
pChembl values 
for chemicals 
Number of PDB files 
found that contain 
human NR 
structures Total with pChEMBL > 5 
AHR 219 170 4.0 - 9.35 20 
CAR - - - - 
ER 7528                      (4586α) (2942β) 
1489                                    
(791α) (698β) 4.14 - 11.00 249 
FXR 799 602 4.21 - 8.7 23 
GR 2021 2029 4 - 10 62 
LXR 1536                      (749α) (787β) 
812                                    
(368α) (444β) 4.09 – 9.00 16 
PPAR 
13358                      
(4034α) 
(3040β)(6284γ) 
5700                      
(1999α) 
(1196β)(2505γ) 
4.00 – 10.74 166 
PXR 463 135 4.00 – 9.15 68 
RAR 
25111                      
(848α) 
(878β)(785γ) 
855                                      
(258α)             
(325β)(272γ) 
4.55 – 10.4 20 
RXR 
2380                      
(1845α) 
(263β)(272γ) 
950                                      
(563α)             
(189β)(198γ) 
4.68 – 10.1 109 
Note: α, β and γ values given in parentheses are the number of chemicals found that are associated 
with binding to either the α, β or γ subunit of the NR 
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  Table 3: The descriptor ranges used for all NR and implemented within the workflow 
Physico-
chemical 
property 
Value 
AHR CAR ER FXR GR LXR PPAR PXR RAR 
VAIM 4.5-6.5 - 4 - 7.5 - 4 - 8.5 4.7 - 7 5 - 7 5 - 7 5 - 7 
HBD < 6 - < 10 - < 15 - - < 5 - 
MW 180 - 900 - 140 - 700 > 900 180 - 610 < 750 < 800 300 - 610 < 550 
HBA < 10 - < 15 - < 15 - - < 10 - 
XLogP < 8 - < -2 - < -1 < 2 - < 0 - 
ECI - - - 150  - 2400 - - - - - 
RB - - - 3- 11 - - - - 3 - 30 
TPSA - - - 15 - 200 - 5 - 150 1.2 - 20 - - 
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Table 4: SMARTS strings and chemical structure of backbone ring for AHR actives. 
 
 
 
 
 
 
SMARTS string Structual Feature
[#7,#6,#8,#16]1[#7,#6,#8,#16][#7,#6,#8,#16][#7,#6,#8,#16]([#7,#6,#8,#16]1)-c1ccccc1
[#6]~1~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~[#6]~[#6]~1-c1ccccc1
[#8,#6,#7,#16]~1~[#8,#6,#7,#16]~[#8,#6,#7,#16]~[#6](~[#8,#6,#7,#16]~[#8,#6,#7,#16]~1)-[#7,#8,#6,#16]-c1ccccc1
[#8,#7,#6]~1~[#8,#7,#6]~[#8,#7,#6]~c2ccccc2~[#8,#7,#6]~1
O=[#6](-[#7]-c1ccccc1)-c1[#7,#6][#7,#6][#7,#6][#7,#6][#7,#6]1
[#7,#6,#8]~1~[#7,#6,#8]~[#7,#6,#8]~2~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~2~[#7,#6,#8]~1
C(=C\c1ccccc1)\c1ccccc1
c1nc2ccccc2s1
[#6]-[#7]-c1ccccc1-[#9,#17]
[#6;A][#7]-c1ccc(-[#9,#17,#1])c(-[#9,#17,#1])c1
L
[O,N,C]
L
[O,N,C]
L
[O,N,C]
L
[O,N,C]
L[N,C,O]
L
[N,C,O]
L
[N,C,O]
L
[N,C,O]
L
[N,C,O]
L
[N,C,O]L
[N,C,O]
L
[N,C,O]L
[N,C,O]
N
S
H3C
NH
L[F,Cl]
C(A)
NH
L
[F,Cl,H]
L
[F,Cl,H]
L
[N,C,O,S]
L
[N,C,O,S]
L[N,C,O,S]
L
[N,C,O,S]
L [N,C,O,S]
L
[N,C,O]L
[N,C,O]
L
[N,C,O]
L
[O,C,N,S]
L
[O,C,N,S]
L
[O,C,N,S]
L
[O,C,N,S]
L
[O,C,N,S]
L [N,O,C,S]
O NH
(a)
L
[N,C]
L[N,C]
L
[N,C]
L[N,C]
L
[N,C]
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Table 5: SMARTS strings and chemical structure of oxygen group for AHR actives. 
 
  
SMARTS string Structual Feature
*~*(~*)=O
*~[#6](~*)-[#8]
c1c*o*1
A
A
A
O
A
A
HO
(a)
(a)
AO
(a)
A
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Table 6: SMARTS strings and chemical structure of oxygen substitute (nitrogen/ chlorine) for AHR 
actives. 
 
 
  
SMARTS string Structual Feature
[#6,#7]~1~[#6,#7]~[#6,#7]~2~[#6,#7]~[#6,#7]~[#6,#7]~[#6,#7]~[#6,#7]~2~[#6,#7]~1
[#7;a]~1~*~*~*~*~*~1
*n1ccnc1
Clc1ccc(cc1)-c1cc(Cl)c(Cl)c(Cl)c1
Clc1ccc(cc1Cl)-c1cc(Cl)c(Cl)c(Cl)c1
Clc1ccc(cc1Cl)-c1ccc(Cl)c(Cl)c1
Clc1cc(cc(Cl)c1Cl)-c1cc(Cl)c(Cl)c(Cl)c1
Cc1c(Cl)c(Cl)c(Cl)cc1-c1ccc(Cl)c(Cl)c1
L[C,N]
L
[C,N]
L
[C,N]
L
[C,N]
L [C,N]
L
[C,N]L
[C,N]
L
[C,N]L
[C,N]
N
(a)
A
A
A
A
A
A
N(a)
N
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
H3C Cl
Cl
Cl
Cl
Cl
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FIGURE TITLES 
Figure 1: Ligand-protein interaction of 4NQA (PDB, 2014), showing potential hydrogen 
bond formation of oxygen groups on the ligand to key residues ARG278 and SER289 within 
the LXR binding domain 
Figure 2: Ligand-protein interaction of 2LBD (PDB, 2014), showing potential hydrogen bond 
formation between the ligand and the key residues LEU330 and ARG319 within the RAR 
binding pocket. 
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Figure 2 
 
 
 
